NexGold Mining Corp. (TSXV: NEXG;OTCQX: NXGCF) (“NexGold” or the “Company”) is pleased to announce certain potential positive outcomes as it works towards the completion of its Feasibility Study (the ...
– Vepdegestrant is the first PROTAC degrader to demonstrate clinical benefit in a Phase 3 trial – ...
Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...
Highlights,D.A. Davidson & CO. decreased its holdings in Provident Financial Services by 5.3% during the fourth quarter.,The company’s latest earnings report showed an EPS of $0.37, falling below ...
Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...
Eli Lilly’s Jaypirca (pirtobrutinib) has been recommended by the European Medicines Agency’s (EMA) human medicines committee ...
CNW/ - Denison Mines Corp. ('Denison' or the 'Company') (TSX: DML) (NYSE American: DNN) today filed its Audited Consolidated ...
10d
HIGHLIGHTS: Solaris has formed an Inter-Institutional working group with the Arutam Shuar People (“PSHA”), ratified through ...
Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and ...
Operator: Welcome to the Cardiff Oncology Fourth Quarter 2024 Financial Results and Business Update Conference Call.
PRNewswire/ - Denison Mines Corp. ('Denison' or the 'Company') (TSX: DML) (NYSE American: DNN) today filed its Audited Consolidated Financial ...
REHOVOT, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback